Abstract 10837: Brain Natriuretic Peptide, but Not Calprotectin or the Long Pentraxin 3 Independently Predicts Stroke in Long-Term Follow-up of Patients With Acute Coronary Syndrome.
Background: Besides its predictive utility for mortality, Brain Natriuretic Peptide (BNP) also predicts stroke in a general population, patients with heart failure and in patients undergoing haemodialysis. Less evidence exists whether BNP or the novel cardiac biomarkers Calprotectin and The Long Pentraxin 3 (PTX3) may predict stroke in patients admitted with acute coronary syndrome (ACS).
Methods: Admission BNP, PTX3 and Calprotectin were measured in 795 patients admitted with symptoms suspective of an ACS. Multivariate analysis was performed using a Cox Proportional Hazard Ratio model. Variables included in the model were BNP, Calprotectin, PTX3 and 18 conventional risk factors for cardiovascular disease including heart failure, hypertension and hs-CRP.
Results: 27 out of 795 patients had an incident of stroke during the follow-up time of two years. Admission level of BNP above the median (median 95pg/mL) significantly predicted stroke (HR 6.7; 95% CI 2.3–19.6, p<0.001, KM survival plot displayed in figure). Following adjustment in the multivariate analysis, BNP remained an independent predictor for stroke (HR 3.2; 95% CI 1.0–9.7, p<0.05). In contrast, neither Calprotectin nor PTX3 provided independent prognostic information for stroke.
Conclusions: Admission level of BNP but not of Calprotectin or PTX3 independently predicts stroke in long term follow-up of patients admitted with chest pain suspective of an ACS.
- © 2010 by American Heart Association, Inc.